Q4 2025 Biogen Inc Earnings Call Transcript
Key Points
- Biogen Inc (BIIB) finished the year strongly, exceeding the upper end of their guidance with a 19% increase in growth products revenue, totaling $3.3 billion.
- The company has made significant advances in its pipeline, with key readouts expected for LEQEMBI and litifilimab, among others.
- LEQEMBI continues to be the market leader in the anti-amyloid therapy market with over 60% market share.
- Biogen Inc (BIIB) has strengthened its balance sheet, ending the year with $4.2 billion in cash and marketable securities.
- The company is actively expanding its early-stage pipeline and has made strategic acquisitions and collaborations, such as with Alcyone Therapeutics, Vanqua, and Dayra Therapeutics.
- Biogen Inc (BIIB) expects total revenue to decline by a mid-single-digit percentage in 2026 compared to 2025, due to competitive pressures in the MS market.
- The company faces challenges with the full reimbursement of the subcutaneous pen for LEQEMBI, which may impact revenue growth.
- There is uncertainty regarding the erosion of the MS portfolio, particularly with the introduction of a biosimilar for TYSABRI.
- The company is still in the process of building capabilities in new therapeutic areas such as lupus and nephrology, which may require significant investment.
- Biogen Inc (BIIB) has not yet found acquisition opportunities that generate value for shareholders, despite actively looking for potential acquisitions.
Please stand by. Good morning. My name is Ruth, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth-quarter and full-year 2025 earnings call and business update. (Operator Instructions) Today's conference is being recorded.
Thank you. I would now like to turn the conference over to Mr. Tim Power, Head of Investor Relations. Mr. Power, you may begin your conference.
Thanks, Ruth, and good morning, everyone. Welcome to Biogen's fourth-quarter and full-year 2025 earnings call. During this call, we will make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, which I encourage you to review. Our earnings release and other documents related to our results as well as reconciliations between GAAP and non-GAAP results discussed on this call can be found in the Investors section of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
